Muriel Fartoukh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muriel Fartoukh has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
Antoine Parrot
Service de Pneumologie et Oncologie Thoracique, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France
13 shared publicationsGuillaume Voiriot
Service de Médecine Intensive Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France
8 shared publications- Antoine Parrot
A Service de Pneumologie , AP-HP, Hôpitaux Universitaires de l'Est Parisien, Pôle TVAR, Hôpital Tenon , Paris , France
7 shared publications - Guillaume Voiriot
Sorbonne Université, Centre de Recherche Saint-Antoine UMRS_938 INSERM, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France
6 shared publications Aude Gibelin
Service de Médecine Intensive Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France
5 shared publicationsAntoine Khalil
Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Radiologie, Sorbonne Université, Paris, France
4 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 90, 101287
Differential impact of the pandemic first wave on chronic respiratory diseases in France
- 15 May 2026
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 90, 101287
Open AccessDifferential impact of the pandemic first wave on chronic respiratory diseases in France
- Open Access
- 17 November 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003580
One-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study
Rationale: COVID-19 pandemic had a significant impact on patients with chronic respiratory diseases (CRD) and was associated with an increased risk of severe outcomes. However, long-term burden of COVID-19 and the dynamics on healthcare utilisation of patients with CRD remain largely unknown. Objective: The objective was to evaluate outcomes and healthcare utilisation trajectories 1 year after hospitalisation for COVID-19 in patients with CRD. Methods: Data were extracted from the French National Health Database (SNDS). All adults with CRD who had a first hospitalisation for symptomatic COVID-19 and discharged alive between March 2020 and January 2021 were included. Postdischarge care trajectories, including any hospitalisations and ambulatory care recorded in the SNDS, over a 1-year period, were analysed using state sequence analysis. Healthcare utilisation patterns between the year prior to and the year following hospitalisation were then compared, and a multinomial logistic regression analysis was performed to identify baseline CRD category associated with trajectory clusters. Results: Among the 40 066 patients with CRD discharged alive, chronic obstructive pulmonary disease was the main CRD followed by asthma, sleep apnoea and interstitial lung disease. Overall, 6913 (17.3%) died at 1 year. Proportion of days alive spent at home without any care decreased from 91.1% to 64.4%. Five distinct clusters of healthcare trajectories were identified: ‘home’ (52%) with a slight increase in healthcare utilisation, ‘home with care’ (22%) with a high healthcare utilisation, ‘extended hospitalisation’ (9.4%) in long-term care or acute care, ‘early death’ (11%) and ‘late death’ (5.1%). Asthma was more often associated with the ‘home’ trajectory, while other CRD categories were more often associated with other clusters. Conclusion: Patients with CRD hospitalised for COVID-19 had heterogeneous 1-year trajectories, characterised by increased healthcare utilisation and risk of death. Asthma was the only CRD category not associated with excess mortality or high healthcare consumption.
- 17 November 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003580
Open AccessOne-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study
Rationale: COVID-19 pandemic had a significant impact on patients with chronic respiratory diseases (CRD) and was associated with an increased risk of severe outcomes. However, long-term burden of COVID-19 and the dynamics on healthcare utilisation of patients with CRD remain largely unknown. Objective: The objective was to evaluate outcomes and healthcare utilisation trajectories 1 year after hospitalisation for COVID-19 in patients with CRD. Methods: Data were extracted from the French National Health Database (SNDS). All adults with CRD who had a first hospitalisation for symptomatic COVID-19 and discharged alive between March 2020 and January 2021 were included. Postdischarge care trajectories, including any hospitalisations and ambulatory care recorded in the SNDS, over a 1-year period, were analysed using state sequence analysis. Healthcare utilisation patterns between the year prior to and the year following hospitalisation were then compared, and a multinomial logistic regression analysis was performed to identify baseline CRD category associated with trajectory clusters. Results: Among the 40 066 patients with CRD discharged alive, chronic obstructive pulmonary disease was the main CRD followed by asthma, sleep apnoea and interstitial lung disease. Overall, 6913 (17.3%) died at 1 year. Proportion of days alive spent at home without any care decreased from 91.1% to 64.4%. Five distinct clusters of healthcare trajectories were identified: ‘home’ (52%) with a slight increase in healthcare utilisation, ‘home with care’ (22%) with a high healthcare utilisation, ‘extended hospitalisation’ (9.4%) in long-term care or acute care, ‘early death’ (11%) and ‘late death’ (5.1%). Asthma was more often associated with the ‘home’ trajectory, while other CRD categories were more often associated with other clusters. Conclusion: Patients with CRD hospitalised for COVID-19 had heterogeneous 1-year trajectories, characterised by increased healthcare utilisation and risk of death. Asthma was the only CRD category not associated with excess mortality or high healthcare consumption.
- Open Access
- 30 September 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-11
Severe autoimmune hemolytic anemia in ICU: a place for emergency plasma exchange? A French multicenter retrospective study
Autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening condition requiring intensive care unit (ICU) admission in severe cases. While corticosteroids and immunosuppressants are standard treatments, their delayed efficacy limits their utility in critical settings requiring rapid hemolysis control. Plasma exchange (PlEx) may offer a rapid intervention, but its effectiveness in severe AIHA remains uncertain. This study aims to assess the clinical characteristics, outcomes, and the potential benefit of PlEx in ICU cases with severe AIHA. We conducted a multicenter retrospective cohort study including patients with severe AIHA admitted to 15 ICUs within the Assistance Publique–Hôpitaux de Paris (AP-HP) network between 2017 and 2024. Clinical, biological, and therapeutic data were collected. A multivariate logistic regression model, an analysis adjusted on a propensity score (PS) and on inverse probability of treatment weighting (IPTW) were used to identify predictors of in-ICU mortality and evaluate the association between PlEx and in-ICU mortality. One hundred forty-eight ICU stays involving severe AIHA hemolytic crises were analyzed. The median age at ICU admission was 61 {48–71} years, with a balanced sex ratio (51% male). Admission median hemoglobin was 5.2 g/dL {4.2–7.2} and in-ICU mortality was 17.6%. Risk factors for in-ICU mortality included age > 60 years, renal replacement therapy, mechanical ventilation, and high-dose intravenous methylprednisolone (HDIM). Therefore, ICU mortality was mainly driven by organ dysfunction rather than anemia severity. Standard corticosteroid therapy (1–2 mg/kg) (OR:0.19 [0.03–0.94], P = 0.05) and PlEx (OR:0.04 [0.004–0.4], P = 0.008) were associated with improved survival. The association between PlEx and outcome persisted after PS (OR: 0.04 [0.001–0.39]; P = 0.012) and IPTW (OR: 0.13 [0.02–0.55]; P = 0.011) adjustment. In this large ICU cohort, severe AIHA was associated with high mortality, driven by organ failure rather than anemia severity. PlEx are associated with survival, suggesting its potential role as a bridge to immunosuppressive therapy in selected cases. Prospective studies are needed to confirm these findings.
- 30 September 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-11
Open AccessSevere autoimmune hemolytic anemia in ICU: a place for emergency plasma exchange? A French multicenter retrospective study
Autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening condition requiring intensive care unit (ICU) admission in severe cases. While corticosteroids and immunosuppressants are standard treatments, their delayed efficacy limits their utility in critical settings requiring rapid hemolysis control. Plasma exchange (PlEx) may offer a rapid intervention, but its effectiveness in severe AIHA remains uncertain. This study aims to assess the clinical characteristics, outcomes, and the potential benefit of PlEx in ICU cases with severe AIHA. We conducted a multicenter retrospective cohort study including patients with severe AIHA admitted to 15 ICUs within the Assistance Publique–Hôpitaux de Paris (AP-HP) network between 2017 and 2024. Clinical, biological, and therapeutic data were collected. A multivariate logistic regression model, an analysis adjusted on a propensity score (PS) and on inverse probability of treatment weighting (IPTW) were used to identify predictors of in-ICU mortality and evaluate the association between PlEx and in-ICU mortality. One hundred forty-eight ICU stays involving severe AIHA hemolytic crises were analyzed. The median age at ICU admission was 61 {48–71} years, with a balanced sex ratio (51% male). Admission median hemoglobin was 5.2 g/dL {4.2–7.2} and in-ICU mortality was 17.6%. Risk factors for in-ICU mortality included age > 60 years, renal replacement therapy, mechanical ventilation, and high-dose intravenous methylprednisolone (HDIM). Therefore, ICU mortality was mainly driven by organ dysfunction rather than anemia severity. Standard corticosteroid therapy (1–2 mg/kg) (OR:0.19 [0.03–0.94], P = 0.05) and PlEx (OR:0.04 [0.004–0.4], P = 0.008) were associated with improved survival. The association between PlEx and outcome persisted after PS (OR: 0.04 [0.001–0.39]; P = 0.012) and IPTW (OR: 0.13 [0.02–0.55]; P = 0.011) adjustment. In this large ICU cohort, severe AIHA was associated with high mortality, driven by organ failure rather than anemia severity. PlEx are associated with survival, suggesting its potential role as a bridge to immunosuppressive therapy in selected cases. Prospective studies are needed to confirm these findings.
- Open Access
- 25 September 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 137-10
Severe hemoptysis: etiologies, management, and outcomes from a single-center experience over the last decade
- 25 September 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 137-10
Open AccessSevere hemoptysis: etiologies, management, and outcomes from a single-center experience over the last decade
- Open Access
- 7 February 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 51, 101234
Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trial
- 7 February 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 51, 101234
Open AccessCombined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trial
- 1 July 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (1) , e222280
Case 327: Exogenous Lipoid Pneumonia
History: A 58-year-old male patient with an active smoking status was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period. The patient had obesity (body mass index, 36), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, the patient was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, and bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. The patient had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38–7.42]; PaO2 level, 67 mm Hg [normal range, 80–100 mm Hg]; PaCO2 level, 102 mm Hg [normal range, 38–42 mm Hg]; bicarbonate [HCO3−], 29 mmol/L [normal range, 22–27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included CT and MRI of the chest without contrast enhancement, and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT.
- 1 July 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (1) , e222280
Case 327: Exogenous Lipoid Pneumonia
History: A 58-year-old male patient with an active smoking status was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period. The patient had obesity (body mass index, 36), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, the patient was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, and bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. The patient had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38–7.42]; PaO2 level, 67 mm Hg [normal range, 80–100 mm Hg]; PaCO2 level, 102 mm Hg [normal range, 38–42 mm Hg]; bicarbonate [HCO3−], 29 mmol/L [normal range, 22–27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included CT and MRI of the chest without contrast enhancement, and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT.
- 1 March 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (3) , e222275
Case 327
A 58-year-old man who was an active smoker was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period (Fig 1). He had obesity (body mass index, 36 kg/m2), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, he was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. He had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38-7.42]; Pao2 level, 67 mm Hg [normal range, 80-100 mm Hg]; Paco2 level, 102 mm Hg [normal range, 38-42 mm Hg]; Hco3- level, 29 mmol/L [normal range, 22-27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included noncontrast chest CT (Fig 2), MRI of the chest without contrast enhancement (Fig 3), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 4).
- 1 March 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (3) , e222275
Case 327
A 58-year-old man who was an active smoker was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period (Fig 1). He had obesity (body mass index, 36 kg/m2), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, he was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. He had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38-7.42]; Pao2 level, 67 mm Hg [normal range, 80-100 mm Hg]; Paco2 level, 102 mm Hg [normal range, 38-42 mm Hg]; Hco3- level, 29 mmol/L [normal range, 22-27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included noncontrast chest CT (Fig 2), MRI of the chest without contrast enhancement (Fig 3), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 4).
- Open Access
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Diagnostic yield of viral multiplex PCR during acute exacerbation of COPD admitted to the intensive care unit: a pilot study
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the leading causes of admission to the intensive care unit, often triggered by a respiratory tract infection of bacterial or viral aetiology. Managing antibiotic therapy in this context remains a challenge. Respiratory panel molecular tests allow identifying viral aetiologies of AECOPD. We hypothesized that the systematic use of a respiratory multiplex PCR (mPCR) would help antibiotics saving in severe AECOPD. Our objectives were to describe the spectrum of infectious aetiologies of severe AECOPD, using a diagnostic approach combining conventional diagnostic tests and mPCR, and to measure antibiotics exposure. The study was bicentric, prospective, observational, and included 105 critically ill patients with a severe AECOPD of presumed infectious aetiology, in whom a respiratory mPCR with a viral panel was performed in addition to conventional microbiological tests. Altogether, the microbiological documentation rate was 50%, including bacteria alone (19%), respiratory viruses alone (16%), and mixed viruses and bacterial species (16%). The duration of antibiotic therapy was shorter in patients without documented bacterial infection (5.6 vs. 9 days; P = 0.0006). This pilot study suggests that molecular tests may help for the proper use of anti-infective treatments in critically ill patients with severe AECOPD.
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Open AccessDiagnostic yield of viral multiplex PCR during acute exacerbation of COPD admitted to the intensive care unit: a pilot study
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the leading causes of admission to the intensive care unit, often triggered by a respiratory tract infection of bacterial or viral aetiology. Managing antibiotic therapy in this context remains a challenge. Respiratory panel molecular tests allow identifying viral aetiologies of AECOPD. We hypothesized that the systematic use of a respiratory multiplex PCR (mPCR) would help antibiotics saving in severe AECOPD. Our objectives were to describe the spectrum of infectious aetiologies of severe AECOPD, using a diagnostic approach combining conventional diagnostic tests and mPCR, and to measure antibiotics exposure. The study was bicentric, prospective, observational, and included 105 critically ill patients with a severe AECOPD of presumed infectious aetiology, in whom a respiratory mPCR with a viral panel was performed in addition to conventional microbiological tests. Altogether, the microbiological documentation rate was 50%, including bacteria alone (19%), respiratory viruses alone (16%), and mixed viruses and bacterial species (16%). The duration of antibiotic therapy was shorter in patients without documented bacterial infection (5.6 vs. 9 days; P = 0.0006). This pilot study suggests that molecular tests may help for the proper use of anti-infective treatments in critically ill patients with severe AECOPD.
- Open Access
- 18 January 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (6) , 734-743
Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial
- 18 January 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (6) , 734-743
Open AccessRespiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial
- Open Access
- 23 December 2022
- Published by Elsevier in Journal of Tissue Viability
- Vol. 32 (1) , 20-25
Feasibility of a repositioning schedule on pressure ulcer prevention in a French Intensive Care Unit: A pre and post-intervention pilot study
- 23 December 2022
- Published by Elsevier in Journal of Tissue Viability
- Vol. 32 (1) , 20-25
Open AccessFeasibility of a repositioning schedule on pressure ulcer prevention in a French Intensive Care Unit: A pre and post-intervention pilot study